Skip to content
Review

Multidisciplinary cardiac case conference overcomes therapeutic inertia in heart failure: achieving guideline-directed therapy in high-risk populations

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

The two-to-five-month HF duration group showed greatest recovery, supporting structured early intervention, in keeping with the STRONG-HF trial, and patients with "stable" disease often overlooked for intensification showed greatest recovery.

Abstract

Therapeutic inertia remains a major barrier to guideline-directed medical therapy (GDMT) in heart failure (HF) with reduced ejection fraction (HFrEF). Patients with advanced chronic kidney disease (CKD), frailty, and established HF are often undertreated. We evaluated whether a multidisciplinary cardiac case conference (MDCC), implemented alongside standard care, could overcome these barriers. To assess GDMT optimisation, left ventricular (LV) recovery, and safety outcomes of an MDCC for HFrEF, with subgroup analyses by renal function, frailty, and HF duration. Over 24 months, 213 patients were referred to a weekly MDCC with 335 reviews conducted. This analysis focuses on consecutive HFrEF patients (n=89) referred for medication optimisation (February 2023-January 2025). The MDCC comprised structured nurse practitioner case presentation, pharmacist review and Heart Failure Specialist input, alongside routine care. Primary outcomes included quadruple therapy achievement and LV ejection fraction (LVEF) change. Subgroup analyses were undertaken by baseline estimated glomerular filtration rate (eGFR), frailty, and HF duration. The cohort included high-risk patients: 44% CKD stage ≥3 (6% eGFR <30), 28% frail, 30% HF <2 months duration, mean age 64±16 years, baseline LVEF 30% (IQR 20-35%). Median 2 MDCC reviews (range 1-9). GDMT: Quadruple therapy increased from 45% to 82% (p<0.001). RAAS inhibition (ACE/ARB/ARNI) 90% to 99%, of those angiotensin receptor-neprilysin inhibitor: 36% to 63%; mineralocorticoid receptor antagonist: 64% to 89%; sodium-glucose cotransporter-2 inhibitor: 67 to 94%; beta-blocker: 94% to 98%. LV Recovery: Mean LVEF improved +12.1±10.8% (p<0.001); 66% improved LVEF category; 37% achieved recovered LVEF ≥50%. HF Duration: Patients with HF for two to five months showed greatest recovery (56% achieved LVEF ≥50%) versus ≥12 months (29%), highlighting a window of opportunity in patients with "stable" disease often overlooked for intensification. Safety: Patients with eGFR <45 (n=27) had stable renal function (GFR +0.3, p=0.87) and 74% achieved quadruple therapy. Frail patients achieved similar LVEF improvement (+11.0% vs +12.4%, p=0.61). There was no significant change in hyperkalaemia, renal dysfunction nor admissions related to medication side effects. Clinical Outcomes: One-year HF hospitalisation 6.7%; mortality 4.5%; loop diuretic use decreased from 47% to 20%. An MDCC achieved 82% quadruple therapy and significant LV recovery. Patients with CKD, frailty, and established HF achieved safe optimisation. The two-to-five-month HF duration group showed greatest recovery, supporting structured early intervention, in keeping with the STRONG-HF trial. An MDCC for heart failure patients overcomes therapeutic inertia, and is efficient and cost-effective with clinical improvements for HF patients regardless of comorbidities.Figure 2 LVEF Flow ChartFigure 1 GDMT Bar Graph

View source

Similar papers

Open access Oct 2026

Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction

Patients with a higher comorbidity burden less often used quadruple therapy and had a worse prognosis, as well as its association with clinical outcomes, according to a prespecified subanalysis of the TITRATE-HF registry.

J. J. N. Krabbe, M. I. Wilde, A. Mosterd et al. · 0 citations
Open access Oct 2026

Traditional cardiovascular risk factors and guideline-directed medical therapy profile in ACHD living with HFrEF. a national referral centre study

The majority of adults with congenital heart disease (ACHD) who develop heart failure present with preserved ejection fraction. Evidence regarding heart failure with reduced ejection fraction (HFrEF) in this population remains limited, particularly in low- and middle-income countries. The aim of this study...

G. Avalos, E. Garcia-Cruz, J. Sánchez Nieto et al. · 0 citations
Open access Sep 2026

Intensive titration for elderly patients with heart failure.

An intensive titration program for HFrEF therapy appears feasible and relatively safe in elderly patients and was associated with short-term clinical and biological benefits.

Lison Benezech, M. Cherbi, O. Toulza et al. · 0 citations
Open access Oct 2026

Impact of age on implementation and tolerability of guideline-directed medical therapy in heart failure with reduced ejection fraction

The need for improved implementation strategies to optimize guideline-directed therapy and dosing levels in the ageing HFrEF population is highlighted, with use of GDMT associated with better clinical outcomes, also among older patients.

J. J. N. Krabbe, M. I. Wilde, W. L. Verloop et al. · 0 citations
Open access Oct 2026

Impact of quadruple guideline-directed medical therapy at discharge on thirty-day mortality in older adults with heart failure and reduced ejection fraction: a real-world registry

The implementation of quadruple guideline-directed medical therapy (GDMT) remains a challenge in clinical practice, particularly among older patients with heart failure and reduced ejection fraction. This vulnerable population is often underrepresented in clinical trials, and concerns regarding frailty and potent...

A. Serrano-García, L. Echeverría, L. Rojas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.